2017
DOI: 10.1038/cddis.2017.121
|View full text |Cite
|
Sign up to set email alerts
|

Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs

Abstract: The current agents used for renal cell carcinoma (RCC) only exhibit the moderate response rate among patients. Development of drug resistance eventually fuels the need of either more potent drugs or new drugs to target the resistant pathways. Oridonin is a diterpenoid isolated from the Chinese medicinal herb Rabdosia rubescens and has been shown to have antitumor activities in many cancers. We previously developed new synthetic methodologies to modify structurally diversified diterpenoids and designed a series… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
16
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 23 publications
(16 citation statements)
references
References 34 publications
(40 reference statements)
0
16
0
Order By: Relevance
“…Oridonin phosphate, another derivative, is reported to induce autophagy, which can enhance apoptosis in human breast cancer MDA-MB-436 cells [583]. A novel analog of oridonin, CYD 6-17, inhibits tumor growth in bladder cancer UMUC3 xenograft mice and renal carcinoma 786-O xenograft mice [584,585]. In addition, drug delivery system is also developed to improve the bioavailability of oridonin.…”
Section: Oridoninmentioning
confidence: 99%
“…Oridonin phosphate, another derivative, is reported to induce autophagy, which can enhance apoptosis in human breast cancer MDA-MB-436 cells [583]. A novel analog of oridonin, CYD 6-17, inhibits tumor growth in bladder cancer UMUC3 xenograft mice and renal carcinoma 786-O xenograft mice [584,585]. In addition, drug delivery system is also developed to improve the bioavailability of oridonin.…”
Section: Oridoninmentioning
confidence: 99%
“…The hit compound, CYD0618 (Figure 3), induced a threefold shrinkage of the tumor volume in a triple-negative breast cancer MDA-MB-231 xenograft model at a dose of 5 mg/kg, showing much higher efficacy than parent oridonin [19]. Later, Zhou et al reported another oridonin analog, CYD-6-17 ( Figure 3), which significantly inhibited renal cell carcinoma tumor growth in vivo by targeting 3-phosphoinositide-dependent protein kinase 1 (PDPK1) and its downstream pathways [20].…”
Section: Thiazole Derivatives With In Vivo Efficacymentioning
confidence: 99%
“…is effect suggests its potential application in combination with chemotherapeutic agents for cancer treatment [33,34].…”
Section: Discussionmentioning
confidence: 99%